Evidence map›Paper›PMID 26579506›Full record

ArticleFrontiers in public health2015

Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China.

Shujia Liang, Zhiyong Shen, Jing Yan, Fuxiong Liang, Zhenzhu Tang, Wei Liu, Wei Kan, Lingjie Liao, Xuebing Leng, Yuhua Ruan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Shujia LiangGuangxi Center for Disease Control and Prevention , Nanning , China.
Zhiyong ShenGuangxi Center for Disease Control and Prevention , Nanning , China.
Jing YanState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Fuxiong LiangGuangxi Center for Disease Control and Prevention , Nanning , China.
Zhenzhu TangGuangxi Center for Disease Control and Prevention , Nanning , China.
Wei LiuGuangxi Center for Disease Control and Prevention , Nanning , China.
Wei KanState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Lingjie LiaoState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Xuebing LengState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Yuhua RuanState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Hui XingState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
Yiming ShaoState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention , Beijing , China ; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Beijing , China.
State Key Laboratory of Infectious Disease Prevention and ControlGuangxi Center for Disease Prevention and Control · CNNational Center for AIDS/STD Control and Prevention,China CDC · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate human immunodeficiency virus (HIV) virologic suppression and drug resistance among HIV-infected patients receiving first-line antiretroviral treatment (ART) in hospitals while community care and outreach through local health workers in Guangxi, China.

designThis was a series of cross-sectional surveys from 2004 to 2012 in Guangxi, supported by the Chinese National HIVDR Surveillance and Monitoring Network Working Group. SETTINGS: Guangxi, China.

methodsDemographic, ART, and laboratory data (CD4(+) cell count, viral load, and drug resistance) were analyzed. Factors associated with virologic suppression were identified by logistic regression analysis.

resultsA total of 780 patients were included in this study. The median treatment duration was 20.6 months (IQR 6.6-35.9). Of 780 study participants, 95.4% of patients (744/780) had HIV virologic suppression. Among these, of the 143 patients who were infected through drug injection, only 10 (7.0%) experienced virologic failure, and the overall prevalence of HIV drug resistance was 2.8% (22/789). Factors associated with virologic suppression in the final multivariate models included self-reported missing doses in the past month (compared to not missing doses in the past month, AOR = 0.2, 95% CI: 0.1-0.6) and initial ART regimen without 3TC (compared to initial ART regimen with 3TC, AOR = 0.2, 95% CI: 0.1-0.4). Moreover, the trend chi-square test showed that the proportion of virologic suppression increased over time from 2004 to 2012 (P = 0.002).

conclusionThis study first demonstrated that HIV patients infected through various transmission routes can achieve an excellent treatment outcome in hospitals at or above the county level for free first-line ART in Guangxi. It is an important of ART education and adherence to intervention for achieving better treatment outcomes.

Indexed as

antiretroviral treatmentChinadrug resistanceHIVvirologic suppression

Identifiers

PMID26579506
PMCPMC4621383
OpenAlexW2175721119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.